GLYCOMIMETICS INC
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
CBIO$14.76+6.0%Stored close · as of Nov 11, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
Checking your notes…
| · · · · · · · · · · · · · · | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · Additional · · · · · Total | |||||||||||||
| · · Common Stock · · Paid-In · · Accumulated · · Stockholders’ | |||||||||||||
| · · Shares · · Amount · · Capital · · Deficit · · Equity | |||||||||||||
| Balance at December 31, 2020 | 49,017,622 | $49,018 | $437,639,991 | $(309,469,553) | $128,219,456 | ||||||||
| Issuance of common stock, net of issuance costs | 3,092,603 | | 3,092 | | 10,696,225 | | — | | 10,699,317 | ||||
| Exercise of options and vesting of restricted stock units | 203,669 | | 204 | | 24,825 | | — | | 25,029 | ||||
| Stock-based compensation | — | | — | | 6,087,286 | | — | | 6,087,286 | ||||
| Net loss | — | | — | | — | | (63,427,437) | | (63,427,437) | ||||
| Balance at December 31, 2021 | 52,313,894 | | 52,314 | | 454,448,327 | | (372,896,990) | | 81,603,651 | ||||
| Issuance of common stock, net of issuance costs | 1,953,854 | | 1,954 | | 4,155,454 | | — | | 4,157,408 | ||||
| Exercise of options and vesting of restricted stock units | 110,050 | | 110 | | (110) | | — | | — | ||||
| Stock-based compensation | — | | — | | 3,857,580 | | — | | 3,857,580 | ||||
| Net loss | — | | — | | — | | (46,688,802) | | (46,688,802) | ||||
| Balance at December 31, 2022 | 54,377,798 | | | 54,378 | | | 462,461,251 | | | (419,585,792) | | | 42,929,837 |
| Issuance of common stock, net of issuance costs | 9,822,930 | | 9,823 | | 28,697,188 | | — | | 28,707,011 | ||||
| Issuance of common stock for services | 24,001 | | 24 | | 35,976 | | — | | 36,000 | ||||
| Exercise of options and vesting of restricted stock units | 169,015 | | 169 | | 116,328 | | — | | 116,497 | ||||
| Stock-based compensation | — | | — | | 3,524,476 | | — | | 3,524,476 | ||||
| Net loss | — | | — | | — | | (36,899,420) | | (36,899,420) | ||||
| Balance at December 31, 2023 | 64,393,744 | | $64,394 | | $494,835,219 | | $(456,485,212) | | $38,414,401 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.